Datasheet for ABIN987896

CXCL2 Protein

Go to Product page

Overview

Quantity:	10 µg
Target:	CXCL2
Origin:	Human
Source:	Escherichia coli (E. coli)
Biological Activity:	Active

Product Details

Sequence:	APLATELRCQ CLQTLQGIHL KNIQSVKVKS PGPHCAQTEV IATLKNGQKA CLNPASPMVK KIIEKMLKNG KS
Characteristics:	Fully biologically active when compared to standard. The ED50 determined by a chemotaxis bioassay using human CXCR2 transfected human 293 cells is less than 100 ng/ml, corresponding to a specific activity of >, 1.0 × 104 IU/mg.
Purity:	> 97 % by SDS-PAGE and HPLC analyses.
Endotoxin Level:	Level Less than 1EU/µg of rHuGRO-beta/CXCL2 as determined by LAL method

Target Details

Target:	CXCL2
Alternative Name:	GRO-beta / CXCL2 (CXCL2 Products)
Background:	The three GRO cDNAs encode 107 amino acid precursor proteins from which the N-terminal 34 amino acid residues are cleaved to generate the mature GROs. There are no potential N-linked glycosylation sites in the amino acid sequences. GRO expression is inducible by serum or PDGF

Target Details

	and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.Similar to other alpha chemokines, the three GRO proteins are potent neutrophil attractants and activators. In addition, these chemokines are also active toward basophils. All three GROs can bind with high affinity to the IL-8 receptor type B. Synonym: GRO-beta / CXCL2, Human. Formulation: Lyophilized from a 0.2μm filtered concentrated solution in 20mM PB, pH 7.4, 50mM NaCl.
Molecular Weight:	7.9 kDa, a single non-glycosylated polypeptide chain containing 73 amino acids.
Pathways:	Cellular Response to Molecule of Bacterial Origin

Application Details

Restrictions:	For Research Use only

Handling

Format:	Lyophilized
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.
Storage:	4 °C